MLTX
MoonLake Immunotherapeutics
11.40$
-0.3%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | +0.0% | -100.0% | – | – | -100.0% | – | – | – | – | – | – | |
| – | 0.0% | +593.6% | +23.2% | +15.7% | +56.6% | +642.3% | +96.3% | +0.4% | +0.8% | +12.5% | – | – | |
| – | – | -238.7% | – | – | – | -842.3% | – | – | – | – | – | – | |
| – | +6.8% | +60.7% | +81.8% | +50.9% | +13.0% | -9.7% | +34.5% | +23.7% | -5.2% | -6.6% | -6.4% | – | |
| – | +28.6% | -1.8% | +1.6% | +6.7% | +25.0% | +19.6% | -0.8% | -1.3% | -14.7% | +68.4% | -26.2% | – | |
| – | +15.8% | +31.9% | +54.3% | +40.9% | +15.1% | -4.2% | +26.3% | +19.1% | -9.8% | +7.3% | -10.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | +0.0% | -100.0% | – | – | – | +11,216.7% | +57.0% | -37.6% | +13.7% | +16.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +53.2% | +58.0% | +12.9% | +16.6% | -55.3% | +271.9% | -37.9% | +21.1% | +115.7% | +150.8% | -85.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.